Download interactions: TXT MITAB-2.5
| Interaction | Interactor | Experiments | Homologs | Category | Interaction Score |
Confidence |
|---|---|---|---|---|---|---|
|
ACTN2
Alpha-actinin-2 |
4 |
20 |
High-throughput |
0.710 | High |
|
|
FHL1
Four and a half LIM domains protein 1 |
1 |
19 |
High-throughput |
0.698 | High |
|
|
PDLI3
PDZ and LIM domain protein 3 |
1 |
15 |
High-throughput |
0.698 | High |
|
|
RHOU
Rho-related GTP-binding protein RhoU |
1 |
12 |
High-throughput |
0.647 | High |
|
|
RYR1
Ryanodine receptor 1 |
1 |
4 |
High-throughput |
0.541 | High |
|
|
RBP2
E3 SUMO-protein ligase RanBP2 |
1 |
1 |
High-throughput |
0.541 | High |
|
|
MYPN
Myopalladin |
1 |
9 |
High-throughput |
0.541 | High |
|
|
MYOZ3
Myozenin-3 |
1 |
1 |
High-throughput |
0.541 | High |
|
|
PALLD
Palladin |
1 |
10 |
High-throughput |
0.541 | High |
|
|
MYOZ2
Myozenin-2 |
1 |
1 |
High-throughput |
0.541 | High |
|
|
MYOTI
Myotilin |
1 |
10 |
High-throughput |
0.541 | High |
|
|
BAG3
BAG family molecular chaperone regulator 3 |
1 |
6 |
High-throughput |
0.479 | High |
|
|
LMNA
Prelamin-A/C [Cleaved into: Lamin-A/C |
1 |
16 |
High-throughput |
0.479 | High |
|
|
VIME
Vimentin |
1 |
15 |
High-throughput |
0.479 | High |
|
|
SQSTM
Sequestosome-1 |
1 |
13 |
High-throughput |
0.479 | High |
|
|
CUL3
Cullin-3 |
1 |
7 |
High-throughput |
0.479 | High |
|
|
DCTN1
Dynactin subunit 1 |
1 |
4 |
High-throughput |
0.479 | High |
|
|
NAA40
N-alpha-acetyltransferase 40 |
1 |
3 |
High-throughput |
0.479 | High |
|
|
BICD2
Protein bicaudal D homolog 2 |
1 |
15 |
High-throughput |
0.479 | High |
|
|
BICD1
Protein bicaudal D homolog 1 |
1 |
14 |
High-throughput |
0.479 | High |
|
|
PCNA
Proliferating cell nuclear antigen |
1 |
1 |
High-throughput |
0.457 | High |
|
|
AGR2
Anterior gradient protein 2 homolog |
1 |
1 |
High-throughput |
0.437 | High |
|
|
PERI
Peripherin |
1 |
15 |
High-throughput |
0.437 | High |
|
|
ALK
ALK tyrosine kinase receptor |
1 |
16 |
Small-scale |
0.437 | High |
Service provided by Combinatics, Japan
Last updated: 15 Jul 2024
